Hyderabad will see lot of  start-up action as Bio Asia starts on 25th Feb and ends on 27th Feb

BioAsia 2019 is themed on Life Sciences 4.0 where the global industry experts will share their thoughts on global trends and ramifications for all industry stakeholders viz. companies, policymakers, health tech companies, startups, hospitals, scientists, etc.

On the sidelines, BioAsia will also organise the 17th edition of Start-up Stage in Hyderabad from February 17th to February 19th. The Start-up Stage at BioAsia 2020 will provide a platform to the most promising start-ups across India to interact with global industry leaders.

As per Klaus Schwab, Founder and Executive Chairman of the World Economic Forum, the fourth industrial revolution is evolving at an exponential rather than a linear pace. These technological advancements are resulting in changing stakeholder expectations (physicians, patients, etc.) and blurring boundaries between industries (resulting in a new set of competitors or potential partners in the market)

When there is disruption across all industries, being in denial is not an option. One key remedy to survive in this world of disruption is to change the game internally by accelerating the speed for innovation and execution. Future success will require a lot of experimentation, as well as some failures. Agility and innovation will become core strengths and critical differentiators for the leading pharma companies.

As per Klaus Schwab, Founder and Executive Chairman of the World Economic Forum, the fourth industrial revolution is evolving at an exponential rather than a linear pace. These technological advancements are resulting in changing stakeholder expectations (physicians, patients, etc.) and blurring boundaries between industries (resulting in a new set of competitors or potential partners in the market)

When there is disruption across all industries, being in denial is not an option. One key remedy to survive in this world of disruption is to change the game internally by accelerating the speed for innovation and execution. Future success will require a lot of experimentation, as well as some failures. Agility and innovation will become core strengths and critical differentiators for the leading pharma companies.

BioAsia provides a platform for disruptive ideas to connect with investors and is a great opportunity for Indian startups.